Company Overview and News
One of the city’s largest land owners won the 14th government tender by paying a record HK$25.1 billion for a plot with gross floor area of 1.42 million sq ft
Developers are forming consortiums to spread the financial risk of bidding for a residential site that could fetch an estimated US$3.25 billion
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Nan Fung Development paid a Hong Kong record of HK$24.6 billion for a commercial site in Kai Tak in May. Now the developer is revealing its plans for the Kowloon East site
Profit boosted by disposal of the group’s interest in Lifestyle Properties to the tune of HK$420.8 million
Commercial plot Area 1F Site 2 at former airport site expected to go for anywhere between HK$14.3 billion and HK$22 billion
Qatar is regaining its appetite for deals. In the past two months alone, the world's richest country per capita invested in Turkey's biggest poultry producer, Russian oil giant Rosneft, and U.K. gas company National Grid.
Mainland Chinese developers have set one record after another at Hong Kong’s land auctions, boosting receipts to a record
The former Kowloon home of Hong Kong’s airport, Kai Tak, which is a core part of the city’s next central business district (CBD), will become an acquisition target as developers bet on corporates moving from Central as rents soar, according to industry experts.
Lifestyle International outbids six rivals for site that may be future home to twin iconic towers
Hong Kong’s stock market is poised to open slightly higher on Monday on hopes for the introduction of the Shenzhen stock connect scheme.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...